DALLAS – ( NewMediaWire ) – October 21, 2024 – Sirona Biochem Corp: Stonegate Capital Partners initiates their coverage on Sirona Biochem Corp (TSX-V:SBM) (FSE: ZSB) (OTC: SRBCF).
To view the full announcement, including downloadable images, bios, and more, click here.
- GlycoProteMim(TM) is a potential standout in the premium skincare market
- Sirona is targeting profitability by 2025, with expected revenue from Allergan Aesthetic and the commercialization of GlycoProteMim(TM) set to drive growth.
- Sirona’s partnerships place it in a strong position to capture market share in the growing global skincare industry.
Click image above to view full announcement.
[email protected]
Source:
Stonegate, Inc.
